
Eli Lilly and Company
LLYHealthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
Financials
Financial Snapshot
Market Cap
$1273.77B
Enterprise Value
$1318.39B
Revenue (TTM)
$86.46B
Net Income (TTM)
$27.58B
Cash & Investments
$4.88B
Net Cash
-$44.62B
Free Cash Flow (TTM)
$19.66B
Operating CF (TTM)
$30.64B
Debt/Equity
1.23
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.04B | $8.03B | $7.41B | $2.44B | $3.68B | $3.91B | $2.21B | $2.93B | $3.42B | $7.27B | $4.88B | |
| Operating Cash Flow | $4.85B | $5.62B | $5.52B | $4.84B | $6.50B | $7.37B | $7.59B | $4.24B | $8.82B | $16.81B | $30.64B | |
| Free Cash Flow | $3.76B | $3.45B | $2.51B | $3.48B | $4.47B | $5.39B | $4.60B | -$3.15B | $3.76B | $8.97B | $19.66B | |
| Capital Expenditure | -$1.09B | -$2.16B | -$3.02B | -$1.35B | -$2.03B | -$1.98B | -$2.99B | -$7.39B | -$5.06B | -$7.84B | -$10.98B | |
| Financing Cash Flow | -$559.8M | $142.6M | -$5.90B | -$2.32B | -$3.14B | -$4.13B | -$5.41B | $3.50B | $1.23B | -$2.21B | -$5.14B |
R&D Spending
R&D (TTM)
$15.38B
R&D Intensity
17.8%
R&D Growth vs Prior
+15.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | $86.46B | |
| R&D Expense | $5.31B | $5.10B | $5.05B | $5.59B | $5.98B | $6.93B | $7.19B | $9.31B | $10.99B | $13.34B | $15.38B | |
| R&D % of Revenue | 25.0% | 25.5% | 23.5% | 25.1% | 24.4% | 24.5% | 25.2% | 27.3% | 24.4% | 20.5% | 17.8% | |
| SG&A | $6.33B | $6.18B | $5.73B | $6.00B | $5.87B | $6.14B | $6.07B | $6.94B | $8.59B | $11.09B | $12.62B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | $86.46B | |
| Cost of Revenue | $5.71B | $4.45B | $4.68B | $4.72B | $5.48B | $7.31B | $6.63B | $7.08B | $8.42B | $11.05B | $14.15B | |
| Gross Profit | $15.51B | $15.53B | $16.81B | $17.60B | $19.06B | $21.01B | $21.91B | $27.04B | $36.63B | $54.13B | $72.31B | |
| R&D | $5.31B | $5.10B | $5.05B | $5.59B | $5.98B | $6.93B | $7.19B | $9.31B | $10.99B | $13.34B | $15.38B | |
| SG&A | $6.33B | $6.18B | $5.73B | $6.00B | $5.87B | $6.14B | $6.07B | $6.94B | $8.59B | $11.09B | $12.62B | |
| Operating Income | $3.87B | $4.25B | $6.03B | $6.00B | $7.21B | $7.93B | $8.65B | $10.79B | $17.04B | $29.70B | $39.83B | |
| Interest Expense | $185.2M | $225.0M | $242.5M | $400.6M | $359.6M | $339.8M | $331.6M | $485.9M | $780.6M | $795.3M | $1.18B | |
| Pretax Income | $3.37B | $2.30B | $3.68B | $5.27B | $7.23B | $6.16B | $6.81B | $6.55B | $12.68B | $25.73B | $34.77B | |
| Net Income | $2.74B | -$204.1M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B | $27.58B | |
| EPS (Diluted) | 2.49 | -0.19 | 3.13 | 8.69 | 6.47 | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 | 30.81 | |
| EBITDA | $5.06B | $4.10B | $5.53B | $6.90B | $8.91B | $8.04B | $8.66B | $8.57B | $18.81B | $31.69B | $44.75B | |
| Shares Out. (M) | 1100.88 | 1052.02 | 1033.67 | 957.53 | 956.59 | 953.65 | 950.18 | 903.28 | 904.06 | 898.00 | 893.40 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.58B | $6.54B | $7.32B | $2.34B | $3.66B | $3.82B | $2.07B | $2.82B | $3.27B | $7.16B | $4.88B | |
| Short-Term Investments | $1.46B | $1.50B | $88.2M | $101.0M | $24.2M | $90.1M | $144.8M | $109.1M | $154.8M | $105.0M | $0.00 | |
| Total Current Assets | $15.10B | $19.20B | $20.55B | $13.71B | $17.46B | $18.45B | $18.03B | $25.73B | $32.74B | $55.63B | $65.26B | |
| Total Assets | $38.81B | $44.98B | $43.91B | $39.29B | $46.63B | $48.81B | $49.49B | $64.01B | $78.71B | $112.48B | $148.07B | |
| Total Current Liabilities | $10.99B | $14.54B | $11.89B | $11.78B | $12.48B | $15.05B | $17.14B | $27.29B | $28.38B | $35.23B | $47.00B | |
| Long-Term Debt | $8.37B | $9.93B | $9.20B | $13.82B | $16.59B | $15.35B | $14.74B | $18.32B | $28.53B | $40.87B | $46.99B | |
| Total Liabilities | $24.73B | $33.31B | $33.00B | $36.59B | $40.81B | $39.65B | $38.71B | $53.14B | $64.44B | $85.94B | $107.80B | |
| Stockholders' Equity | $14.01B | $11.59B | $9.83B | $2.61B | $5.64B | $8.98B | $10.65B | $10.77B | $14.19B | $26.54B | $40.27B | |
| Retained Earnings | $16.05B | $13.89B | $11.40B | $4.92B | $7.83B | $8.96B | $10.04B | $10.31B | $13.54B | $24.47B | $37.97B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.85B | $5.62B | $5.52B | $4.84B | $6.50B | $7.37B | $7.59B | $4.24B | $8.82B | $16.81B | $30.64B | |
| Capital Expenditure | -$1.09B | -$2.16B | -$3.02B | -$1.35B | -$2.03B | -$1.98B | -$2.99B | -$7.39B | -$5.06B | -$7.84B | -$10.98B | |
| Free Cash Flow | $3.76B | $3.45B | $2.51B | $3.48B | $4.47B | $5.39B | $4.60B | -$3.15B | $3.76B | $8.97B | $19.66B | |
| Investing Cash Flow | -$3.14B | -$3.78B | $1.91B | -$8.08B | -$2.26B | -$2.87B | -$3.76B | -$7.15B | -$9.30B | -$10.97B | -$30.41B | |
| Financing Cash Flow | -$559.8M | $142.6M | -$5.90B | -$2.32B | -$3.14B | -$4.13B | -$5.41B | $3.50B | $1.23B | -$2.21B | -$5.14B | |
| Issuance of Stock | $0.00 | $0.00 | $1.66B | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | -$600.1M | -$299.8M | -$4.15B | -$4.40B | -$500.0M | -$1.25B | -$1.50B | -$750.0M | -$2.50B | -$4.11B | -$5.84B | |
| Net Debt Issuance | $2.50B | $3.00B | -$729.3M | $4.69B | $291.6M | $501.4M | -$62.0M | $8.65B | $8.90B | $8.05B | $7.32B | |
| Stock Based Comp. | $255.3M | $281.3M | $279.5M | $312.4M | $308.1M | $342.8M | $371.1M | $628.5M | $645.6M | $626.0M | $698.1M | |
| Net Change in Cash | $915.7M | $1.95B | $1.46B | -$5.66B | $1.32B | $161.4M | -$1.75B | $751.6M | $449.8M | $4.00B | -$4.91B |
Dilution Tracker
Shares Outstanding
941M
5-Year Share Growth
-6.1%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1100.88 | 1052.02 | 1033.67 | 957.53 | 956.59 | 953.65 | 950.18 | 903.28 | 904.06 | 898.00 | 893.40 | |
| Change vs Prior % | — | -4.4% | -1.7% | -7.4% | -0.1% | -0.3% | -0.4% | -4.9% | 0.1% | -0.7% | -0.5% | |
| Stock Issuance | $0.00 | $0.00 | $1.66B | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | -$600.1M | -$299.8M | -$4.15B | -$4.40B | -$500.0M | -$1.25B | -$1.50B | -$750.0M | -$2.50B | -$4.11B | -$5.84B | |
| Stock Based Comp. | $255.3M | $281.3M | $279.5M | $312.4M | $308.1M | $342.8M | $371.1M | $628.5M | $645.6M | $626.0M | $698.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.1% | 77.7% | 78.2% | 78.8% | 77.7% | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% | 83.6% | |
| Operating Margin % | 18.2% | 21.3% | 28.0% | 26.9% | 29.4% | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% | 46.1% | |
| Net Margin % | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% | 31.9% | |
| EBITDA Margin % | 23.8% | 20.5% | 25.7% | 30.9% | 36.3% | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% | 51.8% | |
| FCF Margin % | 17.7% | 17.3% | 11.7% | 15.6% | 18.2% | 19.0% | 16.1% | -9.2% | 8.3% | 13.8% | 22.7% | |
| ROE % | 19.5% | -1.8% | 32.9% | 319.1% | 109.8% | 62.2% | 58.6% | 48.6% | 74.6% | 77.8% | 83.6% | |
| ROA % | 7.1% | -0.5% | 7.4% | 21.2% | 13.3% | 11.4% | 12.6% | 8.2% | 13.5% | 18.4% | 18.6% | |
| ROIC % | 10.6% | -0.5% | 15.6% | 18.2% | 18.1% | 20.4% | 23.5% | 19.8% | 25.7% | 30.2% | 30.5% | |
| R&D / Revenue % | 25.0% | 25.5% | 23.5% | 25.1% | 24.4% | 24.5% | 25.2% | 27.3% | 24.4% | 20.5% | 17.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.3% | -5.9% | 7.6% | 3.8% | 9.9% | 15.4% | 0.8% | 19.6% | 32.0% | 44.7% | |
| Gross Profit | 4.0% | 0.1% | 8.3% | 4.7% | 8.3% | 10.2% | 4.3% | 23.4% | 35.4% | 47.8% | |
| Operating Income | 7.8% | 9.8% | 41.8% | -0.4% | 20.2% | 10.0% | 9.1% | 24.7% | 58.0% | 74.3% | |
| Net Income | 13.7% | -107.5% | 1683.5% | 157.4% | -25.5% | -9.9% | 11.9% | -16.1% | 102.1% | 94.9% | |
| EPS (Diluted) | 14.2% | -107.6% | 1747.4% | 177.6% | -25.5% | -9.6% | 12.3% | -11.7% | 101.9% | 96.0% | |
| Operating Cash Flow | 63.6% | 15.8% | -1.6% | -12.5% | 34.4% | 13.3% | 3.0% | -44.1% | 108.0% | 90.7% | |
| Free Cash Flow | 180.9% | -8.2% | -27.4% | 39.0% | 28.3% | 20.5% | -14.6% | -168.5% | 219.3% | 138.6% | |
| R&D Expense | 10.7% | -4.0% | -0.9% | 10.8% | 6.8% | 16.0% | 3.8% | 29.5% | 18.0% | 21.3% | |
| SG&A Expense | -3.1% | -2.4% | -7.2% | 4.7% | -2.2% | 4.6% | -1.2% | 14.4% | 23.8% | 29.1% | |
| Total Assets | 9.1% | 15.9% | -2.4% | -10.5% | 18.7% | 4.7% | 1.4% | 29.3% | 23.0% | 42.9% | |
| Book Value / Share | -3.1% | -13.3% | -4.3% | -73.4% | 116.0% | 57.6% | 18.1% | 6.5% | 31.2% | 86.5% | |
| Debt | 29.2% | 32.4% | -24.5% | 53.5% | 5.0% | 1.7% | -3.8% | 55.3% | 33.4% | 26.3% | |
| Diluted Shares | -0.4% | -4.4% | -1.7% | -7.4% | -0.1% | -0.3% | -0.4% | -4.9% | 0.1% | -0.7% |
Valuation
P/E (TTM)43.83
10Y Low / Med / High15.12 / 46.58 / 99.99
P/S14.73
10Y Low / Med / High3.82 / 9.30 / 15.44
P/B29.99
10Y Low / Med / High5.78 / 32.64 / 48.99
EV/EBITDA29.46
10Y Low / Med / High17.15 / 31.57 / 63.81
EV/Revenue15.25
10Y Low / Med / High4.09 / 9.76 / 16.11
P/FCF64.79
10Y Low / Med / High21.54 / 47.45 / 184.91
Intrinsic Value Models (per share)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 29.54 | -444.53 | 36.85 | 15.12 | 26.10 | 47.22 | 55.68 | 99.99 | 65.65 | 46.58 | 43.83 | |
| P/S Ratio | 3.82 | 4.45 | 5.53 | 5.64 | 6.58 | 9.30 | 12.18 | 15.36 | 15.44 | 14.81 | 14.73 | |
| P/B Ratio | 5.78 | 7.66 | 12.10 | 48.27 | 28.63 | 29.34 | 32.64 | 48.67 | 48.99 | 36.37 | 29.99 | |
| EV/EBITDA | 17.15 | 23.42 | 22.04 | 20.19 | 19.57 | 34.38 | 41.77 | 63.81 | 38.58 | 31.57 | 29.46 | |
| EV/Revenue | 4.09 | 4.80 | 5.67 | 6.24 | 7.11 | 9.76 | 12.68 | 16.02 | 16.11 | 15.35 | 15.25 |
Analyst Estimates & Quality
Altman Z-Score
9.13
Safe
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $91.10B | $106.45B | $118.73B |
| Net Income | $31.81B | $45.15B | $51.47B |
| EPS | $35.33 | $50.00 | $57.23 |
| # Analysts (EPS) | 15 | 15 | 10 |
Dividends
Dividend/Share (TTM)
$6.69
Dividend Yield
0.49%
Frequency
Quarterly
Next Payment
Dec 10, 2026
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Nov 13, 2026 | Dec 10, 2026 | $1.73 | Quarterly |
| Aug 14, 2026 | Sep 10, 2026 | $1.73 | Quarterly |
| May 15, 2026 | Jun 10, 2026 | $1.73 | Quarterly |
| Feb 13, 2026 | Mar 10, 2026 | $1.73 | Quarterly |
| Nov 14, 2025 | Dec 10, 2025 | $1.50 | Quarterly |
| Aug 15, 2025 | Sep 10, 2025 | $1.50 | Quarterly |
| May 16, 2025 | Jun 10, 2025 | $1.50 | Quarterly |
| Feb 14, 2025 | Mar 10, 2025 | $1.50 | Quarterly |
| Nov 15, 2024 | Dec 10, 2024 | $1.30 | Quarterly |
| Aug 15, 2024 | Sep 10, 2024 | $1.30 | Quarterly |
| May 15, 2024 | Jun 10, 2024 | $1.30 | Quarterly |
| Feb 14, 2024 | Mar 8, 2024 | $1.30 | Quarterly |
| Nov 14, 2023 | Dec 8, 2023 | $1.13 | Quarterly |
| Aug 14, 2023 | Sep 8, 2023 | $1.13 | Quarterly |
| May 12, 2023 | Jun 9, 2023 | $1.13 | Quarterly |
| Feb 14, 2023 | Mar 10, 2023 | $1.13 | Quarterly |
| Nov 14, 2022 | Dec 9, 2022 | $0.98 | Quarterly |
| Aug 12, 2022 | Sep 9, 2022 | $0.98 | Quarterly |
| May 13, 2022 | Jun 10, 2022 | $0.98 | Quarterly |
| Feb 14, 2022 | Mar 10, 2022 | $0.98 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Collaboration and Other Revenue | $1.84B | $2.36B | $3.08B | $5.31B | $4.29B | $4.22B |
| Product | $22.69B | $25.96B | $25.46B | $28.81B | $40.75B | $60.96B |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CHINA | $1.12B | $1.66B | $1.45B | $1.54B | $1.66B | $1.95B |
| Europe | $4.19B | $4.78B | $4.30B | $6.17B | $6.92B | $11.56B |
| JAPAN | $2.58B | $2.37B | $1.75B | $1.67B | $1.81B | $2.13B |
| Other Foreign Countries | $2.42B | — | — | — | — | — |
| UNITED STATES | $14.23B | $16.81B | $18.19B | $21.79B | $30.38B | $43.48B |
| Non-US | — | $2.70B | $2.85B | $2.95B | $4.27B | $6.06B |